EUCRISA safety data for the 4-week pivotal trials*1,2

  • Application site pain resolved within 1 day for 77.6% of patients reporting it3
  • Discontinuation rates due to adverse events were 1.2% for both EUCRISA and vehicle in a pooled analysis3
  • Application site pain resolved within 1 day for 77.6% of patients reporting it3
  • Discontinuation rates due to adverse events were 1.2% for both EUCRISA and vehicle in a pooled analysis3

*Trial 1 and Trial 2.

Back to top

References

  1. EUCRISA® (crisaborole) Full Prescribing Information. December 2018.
  2. Data on File. Pfizer Inc., New York, NY.
  3. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.